Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - WDHD1||cholangiocarcinoma||predicted - sensitive||Pemigatinib||Case Reports/Case Series||Actionable||In a Phase II trial (FIGHT-202), Pemazyre (pemigatinib) treatment in a cholangiocarcinoma patient harboring FGFR2-WDHD1 resulted in a partial response with a decrease in tumor size of 63.6% and progression-free survival of 8.8 months (PMID: 33218975; NCT02924376).||33218975|